INSTRUCTIONS Pharmacologic therapy for female sexual dysfunction
* To take the test online, go to our secure website at http://www.nursingcenter.com/ce/NP.
* On the print form, record your answers in the test answer section of the CE enrollment form on page 28. Each question has only one correct answer. You may make copies of these forms.
* Complete the registration information and course evaluation. Mail the completed form and registration fee of $27.95 to: Lippincott Williams & Wilkins, CE Group, 74 Brick Blvd., Bldg. 4, Suite 206, Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form.
* You will receive your CE certificate of earned contact hours and an answer key to review your results.There is no minimum passing grade.
* Registration deadline is January 31, 2016.
DISCOUNTS and CUSTOMER SERVICE
* Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together and deduct $0.95 from the price of each test.
* We also offer CE accounts for hospitals and other healthcare facilities on nursingcenter.com. Call 1-800-787-8985 for details.
Lippincott Williams & Wilkins, publisher of The Nurse Practitioner journal, will award 3.1 contact hours for this continuing nursing education activity.
Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 3.1 contact hours. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #50-1223.
Your certificate is valid in all states. This activity has been assigned 3.1 pharmacology credits.
The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing educational activities and does not imply Commission on Accreditation approval or endorsement of any commercial product.
Pharmacologic therapy for female sexual dysfunction
General Purpose: To provide information on the research and recommendations for practice for treatment of FSD. Learning Objectives: After reading this article and taking the test, the learner should be able to: 1. Identify the classifications and prevalence of FSD. 2. Recognize the clinical evaluation process and the role of nonpharmacologic treatments. 3. Select pharmacologic therapies targeted for categories of FSD.
1. A linear model of the female sexual response cycle that is focused on the emotional and psychological factors of FSD, can be found in the
a. HRQol questionnaire.
b. Decreased Sexual Desire Screener.
d. PLISSIT model.
2. Which statement concerning FSD is correct?
a. FSD is not reported by premenopausal American women.
b. FOD is the most prevalent category of FSD.
c. Comorbid health conditions may affect the presentation of FSD.
d. Researchers use standard methodology to document prevalence of FSD.
3. The authors' literature search was narrowed to exclude
a. perimenopausal women.
b. women in long-term-care facilities.
c. women experiencing significant personal distress.
d. women under treatment for depression.
4. Which physiologic factors primarily affect sexual function in peri- and postmenopausal women?
a. serotonin and nitric oxide
b. DHEA and serotonin
c. norepinephrine and dopamine
d. circulating androgens
5. FSD secondary to diabetes falls under which FSD category?
6. Which FSD screening instrument was developed specifically for use in primary care?
a. Changes in Sexual Function Questionnaire
b. Decreased Sexual Arousal Screener
c. Brief Sexual Symptom Checklist
7. Diagnostic lab tests for FSD
a. should be based on findings from the history and physical exam.
b. routinely include fasting blood glucose and lipid levels.
c. focus on hormone levels in premenopausal women.
d. determine whether counseling is indicated.
8. Which lifestyle intervention demonstrated a significant increase in sexual satisfaction among postmenopausal women with type 2 diabetes?
a. smoking cessation
b. eating Mediterranean-style diet
c. minimizing alcohol intake
d. keeping physically active
9. Physiotherapy is a suggested nonpharmacologic treatment particularly for
a. sexual pain disorders.
10. A patient who is post total hysterectomy with HSDD is receiving oral estrogen Which treatment in clinical trials has been found effective in increasing desire?
a. transdermal testosterone patch at 150 mcg/day
b. silicone estrogen ring
c. transdermal testosterone patch at 300 mcg/day
d. transdermal estradiol
11. The FDA has not approved topical testosterone treatment for women because of its
a. strong link to endometrial cancer.
b. lack of long-term safety data.
c. significant adverse effect on lipid metabolism.
d. inconsistent effectiveness data.
12. Sexual dysfunction associated with SSRI use may be significantly improved by
a. replacing the SSRI with bupropion twice daily.
b. using bupropion or placebo.
c. increasing the SSRI dosage.
d. adding adjunctive bupropion twice daily.
13. Investigators found that bremelanotide did not increase BP versus placebo when administered at home as needed by which route?
14. Use of PDE-5 inhibitors in women
a. are a standard treatment option for FSAD.
b. do significantly affect genital engorgement.
c. are FDA approved for the treatment of FSD.
d. show promise in treating neurodegenerative disorders.
15. Which statement is correct concerning estrogen therapy for sexual pain disorders?
a. Transdermal estrogen preparations are more effective than local.
b. Topical estrogen provides better relief of VVA than systemic therapies.
c. Systemic estrogen therapy should be a first-line treatment for VVA.
d. Dyspareunia is not relieved by local estrogen therapy.
16. Which recently FDA-approved drug is shown to be effective for postmenopausal women with VVA?
a. as a topical vaginal preparation, did not improve severity scores for dyspareunia in postmenopausal women.
b. can be converted into biologically active steroids.
c. has been granted tentative FDA approval.
d. should be advised only for those with full adrenal function.